The Schaeffer Center is currently in year one of an intervention that expands the role of pharmacists in primary care settings which will lead to a three-year cost savings of more than $30,000,000.

There are 170 million people worldwide with hepatitis C. In a recent USC research study, only 1 in 4 of the hepatitis C patients in their study were willing to undergo treatment and only 16.4% achieved the minimum treatment response. [More on page 16]

USC is a partner in a collaborative grant to build a new network integrating health data from 21 million patients to study congestive heart failure, obesity, and Kawasaki disease. [More on page 16]

A USC Schaeffer analysis of Medicare cuts under the ACA found that a reduction in payments SAVED $7.26 BILLION AT THE EXPENSE OF 39,477 LIVES LOST. [More on page 15]

DIRECTOR’S LETTER

What impact really looks like

PRODUCING RELEVANT RESEARCH is what drives us. This is distinct from—and conceptually different than—high-quality research. Often the latter entails a narrow focus on a small question, at the expense of applying its findings to current policy. From Day One, we knew at the Schaeffer Center that we wanted to produce research of consequence. “Relevant, rigorous, independent research” was the rallying call that brought us together and helped the Center ascend to prominence in just a few short years.

Ensuring we do work of both relevance and consequence requires continual vigilance. This year, we initiated a strategic planning process to help us focus moving forward. I am indebted to Leonard D. Schaeffer, our Advisory Board chair; our Advisory Board members; Jack Knott, the dean at the Sol Price School of Public Policy; Pete VanderVeen, the dean at the School of Pharmacy; and Center faculty and staff for contributing to this important process.

This annual report showcases the relevant, meaningful research conducted by the Schaeffer Center this past year, and exhibits how our mission sets us apart. As you will see, our dedication to assembling the nation’s best researchers and developing a robust data infrastructure is what leads us to produce research with consequence for Los Angeles, California, and the nation.

The premium we place on relevance and consequence is what will always distinguish us. Thank you for taking the time to learn more about our work.

Sincerely,
Dana Goldman
The Leonard D. Schaeffer Center for Health Policy and Economics was established in 2009 at the University of Southern California with a generous gift from Leonard and Pamela Schaeffer. The Center reflects the Schaeffer’s life-long commitment to solving health care issues and transforming the health care system.

Addressing health policy issues requires complex solutions, creative research methods, and expertise in a variety of fields—including medicine, economics and public policy. For this reason, the Schaeffer Center is based on the principle of interdisciplinary research. Resulting from a collaboration between the USC Sol Price School of Public Policy and the USC School of Pharmacy, the Center brings together health policy experts, a seasoned pharmacoeconomics team and other affiliated faculty and scholars from across USC and a number of other distinguished universities.

The Schaeffer Center is committed to developing exceptional capacity to conduct interdisciplinary research, policy analysis, and training. More than 20 distinguished scholars and faculty currently investigate a wide array of topics. Their work is supplemented by visiting scholars and collaborations with other universities, allowing outside researchers to take advantage of the Center’s research infrastructure and data. The Center also is actively engaged in training new investigators with excellent research skills who can be the “innovators of the future.” At the same time, the Center is helping the next generation of health care leaders develop strong management, team-building, and communication skills as part of this training.

With a vision to be the premier research and educational institution recognized for innovative, independent research and a significant contributor to policy and health improvement, the Center’s mission is to measurably improve value in health through evidence based policy solutions, research excellence, transformative education, and private and public sector engagement.
Meet the Staff and Faculty

Core Leadership
Dana Goldman
Director
Jason Doctor
Director, Health Informatics
Geoffrey Joyce
Director, Health Policy

Meet the Staff and Faculty

Back row, from left to right: Brian White, Jason Doctor, Brian Vysnick, Geoffrey Joyce, Michael Meхран, Brian Harper, Seth Seabury, Erin Trish, Danielle Meeker, Jeremy Bardfeld, Steve Fox, Grant Laflamme, Sophie Teng, Basuy Arora. Middle row, from left to right: Sadana Theravath, Oluwaniyi Adelphi, Celina Ng, Joanna Tsuda, Barbara Blackley, Tara Knight, Sarah Axeen, Daniel George, Barbara Blaylock, Tara Knight, Celina Ng, Joann Tusia, Oluwaniyi Aderibigbe.

Meet the Staff and Faculty

Front row, from left to right: Jeffrey McCombs, Devin Stambler, John Romley, Duncan Leaf, Sarah Axeen, Daniel George, Barbara Blaylock, Tara Knight, Celina Ng, Joann Tusia, Oluwaniyi Aderibigbe.

Meet the Staff and Faculty

Meet the Staff and Faculty

Staff
Oluwaniyi Adelphi
Sharepoint Administrator
Alejandro Bugov
Program Analyst
Laura Gasco
Qualitative Analyst
Elizaboe...
Meet the Schaeffer Center Advisory Board

Leonard D. Schaeffer, Chair
Leonard D. Schaeffer was the founding Chairman and CEO of WellPoint, Inc., and was Chairman and CEO of WellPoint’s predecessor company, Blue Cross of California. He is currently a senior advisor to TPG Capital and is the Judge Robert Macri Distinguished Professor of Health Care Policy at USC. He previously served as Administrator of the Health Care Financing Administration. He serves on the boards of Quintiles, the RAND Corporation, the Brooking Institution, USC, and Harvard Medical School (HMS) and is on the advisory boards of HMS’s Department of Healthcare Policy and Research. He chairs the advisory board for the Schaeffer Center for Health Policy and Economics at USC. He has endowed academic chairs at the Brooking Institution, the University of California (Berkeley), Institute of Medicine, and HMS.

Drew Altman, Ph.D.
Drew Altman is President and Chief Executive Officer of the Henry J. Kaiser Family Foundation, one of the nation’s largest private foundations devoted to health. Mr. Altman is a former Commissioner of the New Jersey Department of Human Services. He was also Director of the Health and Human Services programs at the Pew Charitable Trusts and Vice President of the Robert Wood Johnson Foundation. Mr. Altman is a member of the Council on Foreign Relations and the Institute of Medicine. He is a world leader in the foundations world of a founding expert on national health policy.

Lars Birgersson, M.D., Ph.D.
Lars Birgersson is Senior Vice President at Amgen. He was previously the Chief of Staff at the Kaiser Foundation, one of the nation’s largest health plans. He served as Director in Health Policy at Uppsala University in Sweden.

Robert Bradley
Robert Bradley is the Chairman and Chief Executive Officer of Amgen. Mr. Bradley became chairman in January 2013 and Chief Executive Officer in May 2010. He served as the company’s President and Chief Operating Officer from May 2007 to May 2010 and was appointed to the Amgen Board of Directors in October 2011. He joined the company in 2002 as Vice President, Operations Strategy, and served as Executive Vice President and Chief Financial Officer from April 2007 to May 2010. Prior to joining Amgen, he was a Managing Director at Morgan Stanley in London where he had responsibility for the firm’s banking and corporate finance activities in Europe.

John D. Dixman, Ph.D.
John D. Dixman, Ph.D. is a Founder and Managing Partner of JAM Ventures, a life sciences investment firm. Previously Dr. Dixman was Chairman and CEO of Affymetrix, and Chairman and Managing Director of Affymax. He is a Charter Trustee of the University of Washington and former Trustee of The California Institute of Technology and also of The Scripps Research Institute, where he served as Chairman. He is an Honorary Fellow of the Order of Australia. Dr. Dixman holds a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Dixman holds an Honorary Degree of Doctor of Laws from McGill University.

Juanito Joaquín
Juanito Joaquín is WorldWide Chairman, President Johnson & Johnson, a position he assumed in January 2013. A member of the Johnson & Johnson Management Committee, he is responsible for the global pharmaceutical commercial and research and development organizations. A native of Valencia, Spain, Mr. Joaquín holds an undergraduate degree in Economics and two Master’s degrees— one in Business Administration from ESADE Business School in Barcelona, the other in International Management from the Naval Postgraduate School of International Management in Phoenix, Arizona.

Dennis Gillings, CBE, Ph.D.
Dennis Gillings is President of the Johnson & Johnson Chairman and former Chief Executive Officer of Quorums. He began providing statistical consulting and data management service to pharmaceutical clients in 1974 during his tenure as a professor at the University of North Carolina at Chapel Hill. Quorums arose from his consulting activities with pharmaceutical companies in the UK with 10 employees. Dr. Gillings was born and educated in the United Kingdom. Today he serves on several boards and councils. He was honored by the Queen as Commander of the Most Excellent Order of the British Empire in 2014 for services to the Pharmaceutical Industry.

Robert Ingram
Robert Ingram is General Partner of Harden Ventures Partners, a venture capital firm, and serves as Chairman and CEO of GlaxoWellcome and co-led the merger that formed GlaxoSmithKline. He currently serves as head of the GlaxoSmithKline Medical Research & Development organizations. Mr. Ingram is a member of the Johnson & Johnson Management and Scientific Advisory Board of the Janssen Pharmaceutical Companies of Johnson & Johnson and Bristol-Myers Squibb. He is currently a member of the board of directors of Affymax.

Diane Gillings, CBE, Ph.D.
Diane Gillings is President of the Institute of Medicine, where she served as an executive vice president and director of the Board on Children, Family, and Community, and a member of the Institute of Medicine. She has served as President of the National Academy of Sciences for nearly eight years, and as a member of the National Academy of Sciences, Engineering and Medicine since 2010. Prior to that she was President and CEO of Wellcome Trust, a private medical research organization, and editor-in-chief of the world’s largest medical research journal, Nature. She was also a member of the National Academy of Medicine.

Robert Margolis, M.D.
Robert Margolis is Chief Executive Officer of HealthCare Partners, Incorporated. He was a founding and managing partner of HealthCare Partners’ predecessor, California Primary Physicians Medical Group. Dr. Margolis serves as a member of the HealthCare Policy Advisory Council for Harvard Medical School and the Executive Management School Advisory Committee of the School of Public Health at the University of California, Los Angeles. He is also on the boards of the National Committee for Quality Assurance, the California Association of Physician Groups, California Hospital Medical Center, Los Angeles, the Council for Affordable Pharmaceutical Practices, and Martin Luther King, Jr., Hospital.

Michael A. Mussallem
Michael A. Mussallem is Chairman and Chief Executive Officer of Edwards Lifesciences Corporation. Mr. Mussallem has been Chairman and Chief Executive Officer since 2000 when the company spun-off from Baxter International. Prior to his current position, Mr. Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter. Mr. Mussallem is the former Chairman of the Board of Directors of the Advanced Medical Technology Association (AMTA). He is currently on the boards and executive committees of Advamed, California Healthcare Institute, OCTA, and is a trustee of the University of California, Irvine Foundation.

Robert D. Reischauer, Ph.D.
Robert D. Reischauer is a Distinguished Institute Fellow and former President of the Urban Institute. Between 1993 and 1995, he served as the Director of the Congressional Budget Office. He was also a Senior Fellow at the Brookings Institution. Mr. Reischauer is a nationally recognized economist, he frequently contributes to the opinion pages of the nation’s major newspapers, comment on public policy developments on radio and television, and testifies before congressional committees. Dr. Reischauer is the Senior Fellow of the Harvard Institute, one of two public trustees of the Social Security and Medicare Trust funds. He was Vice-Chair of the Medicare Payment Advisory Commission. Judith A. Salerno, M.D., M.S.
Judith A. Salerno is the President and Chief Executive Officer of Susan G. Komen for the Cure. Before joining Komen, she was the Leonard D. Schaeffer Distinguished Executive of the Institute of Medicine (OMI) of the National Academy of Sciences, serving as Executive Director and Chief Operating Officer of the Institute. In that role, she oversaw the National Cancer Policy Forum—a consortium of government, industry, academic, consumer, and other representatives that identifed and examined emerging high-priority policy issues in cancer care. Dr. Salerno was Deputy Director of the National Institute on Aging (NIA), directed the continuum of Geriatrics and Extended Care Programs for the U.S. Department of Veterans Affairs (VA), and was Associate Chief of Staff at the VA Medical Center in Washington, D.C. David Schleifer
David Schleifer is the Independent Director of Juniper Networks & Maxwell Technologies, as well as the retired Chairman and Chief Executive Officer of Caradigm. He has been in the medical device industry for the last 30 years. Starting in 1995 he began a focus on improving the sale delivery of intravenous drugs while President & CEO of Axio Medical Systems. After being acquired by Cardinal Health in 2014, he is now Chairman, he expanded his focus on hospital medication safety and preventing hospital acquired infections. Mr. Schleifer served as Chairman and Chief Executive Officer of Caradigm, the Biogroup global medical device company spun-out from Cardinal Health, until his retirement in February 2011.

Tommy Wright, M.D.
Timothy M. Wright is the Global Head of Research at Development at Astrazeneca Pharmaceuticals. He is a member of the Pharmaceutical Executive Committee and the Innovation Management Board at Novartis. Prior to current appointment, Dr. Wright served as Senior Vice President and Global Head of Translational Sciences at the Novartis Institutes for BioMedical Research for four years. He joined Novartis in 2010 as Deputy Head of Exploratory Clinical Development for Translational Research. Previously, Dr. Wright was the Deputy Director of the National Cancer Institute’s Division of Cancer Prevention and Director for Inflammation at Fiber Angle Research and Development in the United States. He has served on national boards for Rheumatology and Clinical Immunology at the University of Pittsburgh where he was awarded an endowed professorship in 1990.
The 2013 Economic Report of the President is the Obama Administration’s annual overview of the country’s economic progress and policies. Featured in the section on the administration’s health care agenda was a Schaeffer Center study on cancer costs.

The study, led by Tomas Philipson alongside Dana Goldman and Darius Lakdawalla, compared life expectancy and treatment costs between cancer patients in the United States and the European Union. From 1983 to 1999, spending per cancer patient rose $16,700 more than European spending. In the same period, the life expectancy of cancer patients rose .4 years over European patients. By 1999, cancer patients in the United States had a life expectancy 1.8 years longer than European patients.

The Economic Report used the findings to elaborate on medical productivity in the United States and to demonstrate how sizable gains in spending have the potential to improve specific health outcomes.

“Faster growth in spending on cancer treatment in the United States than in Europe over this period is sometimes mistakenly taken to indicate the inefficiency of medical care, but it is also the case that the improvement in life expectancy for cancer patients was greater in the United States than in Europe,” the administration wrote of Philipson’s research.

While Philipson’s study suggests cancer treatments are an area where high spending can have high value, the report also cites a study by Dana Goldman concerning high costs with low value. In his research, Goldman points to the overuse of expensive medical technologies with low medical value including coronary artery bypass graft surgery, hysterectomy, and cataract surgery.

The report elaborates that inefficiencies, including the type of overuse Goldman’s study investigated, account for 13 to 26 percent of national health expenditures, and that understanding and eliminating them would allow for huge opportunities in improving quality of care.
Researchers have also found that delaying the aging process would extend life more than separate advances in treatments for cancer or heart disease, and that it would bring better economic returns. Their study was the first to examine the costs and health returns on developing therapies for delayed aging.

“If we can age more slowly, we can delay the onset and progression of many disabling diseases simultaneously,” Goldman said. “Shifting the focus of medical investment to delayed aging instead of targeting diseases individually would lead to significant gains in physical health and social engagement.

“We see extremely large population health benefits, and the benefits will extend to future generations. There are major fiscal changes, but those are manageable with reasonable policy changes, and the economic value of such a shift is too large to ignore,” Goldman said.

“We may need to take a closer look at these policies that presume that age, health decline, and dependency all go hand-in-hand.”

Dana Goldman

Securing the Future for Older Adults

RETIRED MAY never be the same again. The Great Recession decimated the retirement savings for many, and older workers in particular struggle to recover. As a result, working longer will become a necessity. The financial security of a large segment of society is only now beginning to come into focus. Last July, the Federal Reserve sought to better understand the unique position of older adults in a post-crisis economy by hosting a Forum on Financial Experiences of Older Adults.

Julie Zissimopoulos moderated and participated in two panels on older adults’ financial status.

“The Federal Reserve generally deals with very macro problems,” said Zissimopoulos. “But everything they do impacts individuals. The panelists and I were bringing it to the individual level. How are older individuals doing? What are the challenges they will face in securing their financial future?”

Zissimopoulos’ research has delved into specific facets of older Americans’ financial lives. As she told the Federal Reserve audience, the number of workers over age 65 in the workforce has been steadily rising since 1990. Along with an aging workforce comes a rising rate of self-employment as well, as older individuals may step back from their original careers to start others based on different interests or other changes in their lives.

“Self-employment can better accommodate any work-limiting health condition. So those with disabilities seem to be able to find a better work environment as their own boss,” she said.

Rather than taking jobs away from the young or creating a drain on resources, as many believe, older workers contribute both to economic growth and the financial stability of Social Security. Policy, says Zissimopoulos, plays a significant role in encouraging longer work lives and reducing the disincentives to working longer.

“What I wanted to bring out were some of the challenges and constraints, and more importantly, highlight where good policy might be able to help,” Zissimopoulos said.
An Affordable Care Act Alternative

Scholars Design a New and Improved Health Care Insurance System

Staying true to the Schaeffer Center mission of conducting innovative research, scholars dared to imagine what a completely new health care system could look like. The policy proposal that emerged from their work has fueled a conversation about the values that underlie health care decisions.

Darius Lakdawalla and Dana Goldman were members of a team of researchers that released a report sponsored by the American Enterprise Institute (AEI) titled “Best of Both Worlds: Uniting Universal Coverage and Personal Choice in Health Care.”

“We think that what Americans are looking for is a solution that combines choice and market opportunities with a concern and compassion for poorer and more disadvantaged groups,” said Lakdawalla, lead author of the report. The proposal is not a revision of the Affordable Care Act (ACA) but a “start-from-scratch” approach that describes the ideal health care system in which the government provides basic coverage but private insurers are able to set prices that cover their costs.

“That feels to me more of an American solution than the one we have in place,” Lakdawalla said.

“We don’t want to live in a world where people can’t get access to care. But in general we find that private companies do a lot better job of targeting care that works for patients who need it and avoiding wasteful types of medical care,” he said.

The report charts a path to universal coverage without mandates. It removes the income tax exemption for employer-based health insurance, which would unbundle health insurance from employment. It also would remove barriers to long-term insurance contracts to protect Americans from rate increases that could occur after a major illness.

Only those who use the most health services and have the highest incomes would pay more than they do now.

“The heart of the policy issue is how we deal with costs,” Lakdawalla said. “Exchanges in principle are a good idea. The ACA takes some good steps but it doesn’t go nearly far enough in a number of directions.”

AEI is a private, nonpartisan, not-for-profit institution dedicated to research and education on issues of government, politics, economics, and social welfare.

Congressional Testimony on FECA

Congress Solicits Advice from Schaeffer Faculty on Workers’ Compensation

In July 2013, the Department of Labor proposed reforms to the Federal Employees Compensation Act (FECA) which provides federal employees injured at work with workers’ compensation benefits. The Department proposed a flat rate of 70 percent of a worker’s wages (adjusted for inflation) before they were injured, regardless of the worker has dependents.

Seth Seabury testified to a subcommittee of the U.S. Congress that the proposed reforms made FECA benefits both less adequate and equitable. He testified that, as an example, a flat rate as proposed does not adjust when workers have dependents, and those workers with families would receive far fewer benefits proportionally. Nor did the proposed changes factor in lost career growth and the accompanying salary increases.

“If you fail to account for lost career growth, if you don’t consider the impact a worker’s injury has not just today but on the rest of their working life,” Seabury said, “you can really underestimate the long-term consequences of the injury.”

The point of my testimony,” he said, “was really to describe the best way to evaluate the adequacy of worker’s compensation benefits.”

Seabury has spent much of his career evaluating the economic impacts of disabling injuries and considering how well the worker’s compensation system serves disabled workers. The proposed reforms were tied in with the 2013 Postal Reform Act, which is currently stalled in Congress.

“I’m hopeful that in the long run, when agencies try to make changes to their workers’ compensation benefits, this testimony and this body of work in general helps clarify there’s a right way to do it—and that’s to incorporate the full potential effects of a workplace injury.”

Seth Seabury (far right), testifying in front of the U.S. House of Representatives.

“A path to universal coverage without mandates feels to me like more of an American solution than the one we have in place”

Darius Lakdawalla

“If you fail to account for lost career growth... you can really underestimate the long-term consequences of the injury.”

Seth Seabury
Does the Medicare “Donut Hole” Affect Seniors?

A Schaeffer Center study finds that seniors’ prescription drug use falls slightly because of a gap in insurance coverage.

More than two million Americans fall into the so-called “Donut Hole” in Medicare, a calculation that leaves a gap in coverage for prescription drugs. At a certain cost threshold, a senior must pay out of pocket for half of a brand-name drug’s cost until the expenses reach another threshold.

Dana Goldman, along with the Schaeffer Center’s Julia Zissimopoulos and Dana Goldman, find that the donut hole leads seniors to pare back on their prescription drugs. In the Journal of Health Economics, the authors report that, for diabetics, the declines in use were modest and concentrated among higher cost, brand-name medications. Demand for high-cost medications such as antipsychotics, anti-asthmatics, and drugs of the central nervous system declined by up to 18 percent. Less costly drugs such as generic beta blockers, ACE inhibitors, and antidepressants declined by up to 5 percent. Despite lower use, there was no apparent increase in other medical services.

Geoffrey Joyce, along with the Schaeffer Center’s Julie Zissimopoulos and Dana Goldman, find that the donut hole leads seniors to pare back on their prescription drugs.

In our analysis, a reduction in Medicare payments saved $26 billion, at the expense of 39,477 lives, or about $1.14 billion per life lost,” Vivian Wu said. “Some may argue that it’s a costly intervention while others may think it’s worth it. Regardless of what one might think, we need to bring these numbers to the table and be transparent about the tradeoffs we are making.”

We and a colleague designed a study to better understand the impact of the cuts using data from 1997 when similar permanent reductions were made. The results showed that mortality rates differed between hospitals that experienced smaller cuts and those hit with larger cuts, suggesting that reductions can lead to poorer health outcomes.

“inefficiency is not a universal phenomenon,” Wu said. “This type of broad payment cut could contribute to widening gaps in quality between health care organizations.”

Nudging Doctors to Not Overprescribe Antibiotics

RESEARCHERS USE BEHAVIORAL ECONOMICS TO IMPROVE TREATMENT OF ACUTE RESPIRATORY INFECTIONS

Overprescribing antibiotics for acute respiratory infections caused by viruses can be dangerous and costly. Yet, efforts to educate physicians on prescription guidelines have had little impact.

So a team of researchers that includes the Schaeffer Center’s Jason Doctor, Tara Knight, and Daniella Meeker are taking a different approach. They’re testing three new interventions based on behavioral economics, an evolving body of research that recognizes that people don’t always make rational decisions and need to be nudged in the right direction with various incentives.

In this experiment, the team periodically relays to clinicians how their rate of inappropriate antibiotic prescriptions compares with that of their peers. Social standing is a strong motivator, behavioral economists have found. Another intervention prompts the physicians to write down his or her justification for prescribing an antibiotic, commitments like these are effective in changing behavior. The final effort provides doctors with a list of treatment alternatives and materials to give to patients.

“Most quality improvement efforts have used audits or pay-for-performance incentives to try to change what providers do, but they ignore social influences that affect all people, including physicians.”

Jason Doctor

POLICYMAKERS MUST WEIGH HEALTH EFFECTS AGAINST COST SAVINGS

Policymakers face a difficult set of decisions as the impact of Medicare payment cuts enacted as part of the Patient Protection and Affordable Care Act (ACA) take hold. As Schaeffer Center work shows, they will be weighing cost savings against lives lost.

Understanding the Impact of ACA Medicare Cuts

Policymakers face a difficult set of decisions as the impact of Medicare payment cuts enacted as part of the Patient Protection and Affordable Care Act (ACA) take hold. As Schaeffer Center work shows, they will be weighing cost savings against lives lost.

“Some may argue that it’s a costly intervention while others may think it’s worth it. Regardless of what one might think, we need to bring these numbers to the table and be transparent about the tradeoffs we are making.”

We and a colleague designed a study to better understand the impact of the cuts using data from 1997 when similar permanent reductions were made. The results showed that mortality rates differed between hospitals that experienced smaller cuts and those hit with larger cuts, suggesting that reductions can lead to poorer health outcomes.

“inefficiency is not a universal phenomenon,” Wu said. “This type of broad payment cut could contribute to widening gaps in quality between health care organizations.”

Most quality improvement efforts have used audits or pay-for-performance incentives to try to change what providers do, but they ignore social influences that affect all people, including physicians.”

Jason Doctor
New Grant Leverages Patient Data

Researchers in Southern California, including the Schaeffer Center’s Jason Doctor, have been awarded funding to create a stakeholder-governed network that will integrate data from more than 21 million patients. The Schaeffer Center and their partners were selected for this grant by the Patient-Centered Outcomes Research Institute (PCORI), an independent nonprofit organization authorized by Congress in 2010 to conduct research aimed at helping both patients and healthcare providers make informed decisions.

The newly created network called the patient-centered SCAlable National Network for Effectiveness Research (pSCANNER) will integrate data from numerous robust data bases. Tapping into these existing data bases will allow for advances in the research capabilities of scholars, as well as improvements in outcomes for patients.

Researchers will utilize the network’s capabilities to study congestive heart failure, Kawasaki disease, and obesity. Patients, clinicians, and administrators from across the country have agreed to contribute to the governance of pSCANNER, as well as the prioritization of research questions.

By forming this network and allowing secure access of patient information to researchers across the country, strides can be made in these important fields. PCORI, the Schaeffer Center, and their many partners are focused on providing high-quality data, research, and analysis that will be translated into better practices and outcomes for clinicians and patients alike.

“While antiviral therapy can lead to viral eradication and reduced event risk, its effectiveness under real-world clinical conditions is limited.”

Jeffrey McCombs

JAMA and Treating Hep C

In a study of Veterans Affairs (VA) patients with hepatitis C (HCV) led by Schaeffer Center’s Jeffrey McCombs, and published by JAMA Internal Medicine, only a minority of patients were willing to start treatment and fewer still achieved the undetectable viral loads that appear to be associated with decreased rates of illness and death.

HCV is estimated to affect as many as 170 million people worldwide and an estimated 3.2 million people in the United States. Patients with HCV are at risk of developing liver-related complications such as cirrhosis, liver failure, and the cancer hepatocellular carcinoma (HCC), according to the study. However, sometimes patients with HCV go untreated because of adverse effects from available treatments.

McCombs, of the Schaeffer Center, and colleagues sought to describe the progression of HCV in clinical practice by examining the time to liver-related clinical events and death in a group of 28,769 patients from the VA HCV clinical registry.

Of the patients, only 24.3 percent were willing to start treatment, and 16.4 percent of treated patients achieved an undetectable viral load. The study reports that death rates were 6.8 per 1,000 person-years for patients who achieved viral suppression vs. 21.8 per 1,000 person-years in patients who did not meet that goal. Patients who achieved undetectable viral loads also reduced their risk of liver-related events by 27 percent, according to the results.

“While antiviral therapy can lead to viral eradication and reduced event risk, its effectiveness under real-world clinical conditions is limited by adverse effects and other factors. In this study, only 1 in 4 patients with HCV and a detectable viral load were willing to initiate treatment. Once treated, only a fraction of patients achieved the minimum treatment response of a single undetectable viral load test,” said McCombs.

SCHAEFFER CENTER RESEARCH UNCOVERS HOW HEALTH WEBSITES USE PERSONAL SEARCH DATA

Imagine you’re in need of some basic information about a sensitive health topic. Your first stop is likely the Internet, and you’re probably visiting with the assumption your search stays private. But do health sites really keep your information out of third parties’ hands?

The Schaeffer Center’s Marco Huesch conducted his own experiment to find out. Using privacy and interception software, he sampled 20 popular health websites to determine whether searches about cancer, depression, and herpes were tracked or leaked to third parties. He found every site had at least one third party element, and usually more. Thirteen sites had at least one tracking element. Furthermore, seven provided search information to third party tracking groups.

Clearly, there are major holes in current regulation and policy to protect privacy, which could have major consequences.

“The ramifications could be simple embarrassment to discrimination in the labor market. Marketers could also make a deliberate decision to not advertise particular goods and services to an individual based solely on the privately gathered information,” Huesch said.

Huesch published his research in the Journal of the American Medical Association. His work garnered media attention worldwide and he appeared in both the New York Times and on National Public Radio. Following the publication of his work, Illinois Attorney General Lisa Madigan wrote a letter to eight executives at major health sites asking them to disclose how much information they capture, whether they share it with third parties, and if so, who the parties are.

“Health-related information, which would be protected from disclosure when said in a doctor’s office, can be captured, shared, and sold when entered into a website,” Madigan wrote. “These concerns are likely to be overlooked by consumers, as the disclosures about capturing and sharing their information are often buried in privacy policies not found on websites’ main pages.”

In the still-evolving field of online privacy regulation and legislation, Huesch’s research has already caused ripples.

Think Before You Google It: Online Privacy and Health

“Health-related information, which would be protected from disclosure when said in a doctor’s office, can be captured, shared, and sold when entered into a website”

Lisa Madigan
Illinois Attorney General

NATIONAL IMPACT
Helping Californians Understand the Affordable Care Act

California is facing unprecedented times. With the launch of Covered California, the state’s health benefit marketplace created under the Patient Protection and Affordable Care Act (ACA), Californians are getting health insurance in fundamentally new ways.

“There is probably no greater health policy challenge facing California than implementing the Affordable Care Act,” said Dana Goldman. Covered California provides a way for people to shop for health insurance and apply tax credits that lower the cost of premiums.

“It’s vital that we construct a marketplace for the uninsured, because California leads the nation in the number of uninsured,” added Goldman.

Goldman sits on Covered California’s Plan Management and Delivery System Reform Advisory Group and has been integral in helping build in consumer choice functions that let people more easily shop for their insurance. As a nationally recognized health economist, Goldman also plays an important role as an objective expert.

“Most members have a stake in the system. But we’re taking a very independent and objective view from a health policy perspective,” he said.

In February 2013, USC’s Sol Price School of Public Policy and the Schaeffer Center hosted a panel in Sacramento to examine the health care exchange. The panel included Peter Lee, the executive director of Covered California, the California Health Benefit Exchange; Schaeffer Center Senior Fellow Bob Kocher, former Special Assistant to President Obama for Healthcare and Economic Policy; Jay Hansen, Chief Strategy Officer for the California Medical Association; and Goldman.

In the forum, Goldman presented the Schaeffer Center’s research on consumer uncertainty about health plans. When one study asked employees about their insurance deductibles, only about one-half could identify it correctly. He also pointed to his research into the Medicare Part D prescription drug coverage plan, in which he found that few people chose the best plan for their needs and often didn’t choose the most generous plan.

Goldman cautioned that if California consumers, and the 6 million uninsured, do not fully understand their options, the consequences could hurt them. “You may see generous plans eroding over time in the exchange,” he said, because consumers aren’t optimally choosing the best plans. “We have to be careful about monitoring what’s going on.”

Evaluating Hospital Pricing Policies

STUDY FINDS THAT CALIFORNIA’S LAW METS GOAL TO PROVIDE AFFORDABLE CARE

California Hospitals have met and exceeded the requirements of the 2006 “fair pricing” law designed to protect uninsured patients from high medical bills, Glenn Melnick has found.

“The law should be a model for other states enacting similar legislation,” wrote Melnick in a recently published study. By 2011, most hospitals had adopted financial assistance policies to make care more affordable for the state’s 6.8 million uninsured residents.

“Although hospitals may collect less revenue as a result of these policies, they will also incur reduced collection costs and improve their reputations in their local communities,” Melnick and University of Southern California USC colleague Katya Fonkych shared in their article published in Health Affairs.

Many uninsured residents rely on hospital emergency departments for their medical care. Because they did not have insurance, hospitals typically billed the uninsured at a rate four times higher than that paid by insured patients.

Most California hospitals reported that they now offer free care to uninsured patients who have incomes at or below 100 percent of the federal poverty level, Melnick’s study found.

“The administrative structure and costs of complying with the law do not appear overly burdensome, and it seems that once hospitals began to explicitly evaluate their prices to uninsured patients, as required by the law, they offered more affordable prices—especially to the lowest income groups,” Melnick and Fonkych wrote.

“The law should be a model for other states enacting similar legislation.”

Glenn Melnick

SCHAEFFER CENTER OFFERS UNBIASED, OBJECTIVE INFORMATION FOR THE STATE’S NEW HEALTH EXCHANGE

California is facing unprecedented times. With the launch of Covered California, the state’s health benefit marketplace created under the Patient Protection and Affordable Care Act (ACA), Californians are getting health insurance in fundamentally new ways.

“There is probably no greater health policy challenge facing California than implementing the Affordable Care Act,” said Dana Goldman. Covered California provides a way for people to shop for health insurance and apply tax credits that lower the cost of premiums.

“It’s vital that we construct a marketplace for the uninsured, because California leads the nation in the number of uninsured,” added Goldman.

Goldman sits on Covered California’s Plan Management and Delivery System Reform Advisory Group and has been integral in helping build in consumer choice functions that let people more easily shop for their insurance. As a nationally recognized health economist, Goldman also plays an important role as an objective expert.

“Most members have a stake in the system. But we’re taking a very independent and objective view from a health policy perspective,” he said.

In February 2013, USC’s Sol Price School of Public Policy and the Schaeffer Center hosted a panel in Sacramento to examine the health care exchange. The panel included Peter Lee, the executive director of Covered California, the California Health Benefit Exchange; Schaeffer Center Senior Fellow Bob Kocher, former Special Assistant to President Obama for Healthcare and Economic Policy; Jay Hansen, Chief Strategy Officer for the California Medical Association; and Goldman.

In the forum, Goldman presented the Schaeffer Center’s research on consumer uncertainty about health plans. When one study asked employees about their insurance deductibles, only about one-half could identify it correctly. He also pointed to his research into the Medicare Part D prescription drug coverage plan, in which he found that few people chose the best plan for their needs and often didn’t choose the most generous plan.

Goldman cautioned that if California consumers, and the 6 million uninsured, do not fully understand their options, the consequences could hurt them. “You may see generous plans eroding over time in the exchange,” he said, because consumers aren’t optimally choosing the best plans. “We have to be careful about monitoring what’s going on.”
Better Quality and Lower Costs Through Clinical Pharmacy Integration

In October 2012, the Centers for Medicare and Medicaid Services awarded USC researchers $12 million for a project that places pharmacy teams into 10 clinics in underserved neighborhoods of Los Angeles. The pharmacists, the majority of whom are bilingual, interview new patients to identify any problems, consult with their primary care physicians, order labs, and provide education and follow-up care.

Early results have been positive coming in from the project this year. “Let alone the medication aspect, just having someone spend time with patients, to sit down and talk to them about their disease makes a huge difference,” said Geoffrey Joyce. “We’ll probably see some impact just from that.”

The program is still in an early stage, but researchers have already seen reductions in average levels of blood sugar in patients with Type 2 diabetes as well as lower blood pressure.

Minorities and low-income individuals die earlier and have poorer health than Caucasians and higher-income individuals. Understanding these health disparities, especially among aging minorities, is a critical first step in closing the significant health gap.

The Schaeffer Center’s center-within-a-center, the Minority Aging Health Economics Research Center, has partnered with Ricardo Basurto-Davila, a health economist at the Los Angeles County Department of Public Health, to investigate how policy can improve the health of Los Angeles’ minority aging population.

By using a microsimulation model of health and economic outcomes that looks deeply into data about the population of Los Angeles County, the research predicts how specific policies will affect long-term health outcomes and health care costs. In particular, the project is exploring the potential benefits of policies aimed at reducing the risk of diabetes and cardiovascular disease in older adults, two diseases that are more prevalent in Los Angeles’ low-income and minority communities.

“We’re working with the Department of Public Health to develop a tool that policymakers at the local level can use to understand the impact on health and economic outcomes of different policies,” said Julie Zissimopoulos who leads the Minority Aging Health Economics Research Center along with Dana Goldman.

Zissimopoulos added that Los Angeles is a critical place to study health disparities because the current makeup of its population reflects the future population. Looking forward, the Center plans to expand both the collaboration and the tool to consider age groups beyond older adults.

In 2012, the Schaeffer Center was awarded a prestigious grant by the National Institutes of Health to establish a Resource Center for Minority Aging Research. The center created by this grant is called the Minority Aging Health Economics Research Center. The LA County collaboration is one of the initial projects of the Center.
High Hospital Costs, Better Care?

INTERESTING TO FOCUS THIS QUESTION IN A PEDIATRIC CONTEXT. THE RESEARCHERS STUDIED HOSPITAL RECORDS FOR CHILDREN WITH CONGENITAL HEART DISEASE (CHD), A RARE CONDITION THAT REQUIRES SURGERY. THE DISEASE IS EXPENSIVE TO TREAT, AND CAN AFFECT A CHILD’S HEALTH IN ADULTHOOD, THEREBY AFFECTING QUALITY OF LIFE.

PREVIOUS STUDIES, DONE MOSTLY AMONG ADULTS, HAVE FOUND THAT TOP-PERFORMING HOSPITALS SPENT MORE ON CARE BUT HAD HIGHER RATES OF SURVIVAL. BUT NOT MANY STUDIES HAVE BEEN DONE AMONG CHILDREN. ROMLEY AND HIS TEAM THOUGHT IT WOULD BE INTERESTING TO FOCUS THIS QUESTION IN A PEDIATRIC CONTEXT.

RESEARCHERS FIND EVIDENCE OF GROWING DRUG-RESISTANCE AND ARGUE TO PROCEED WITH CAUTION WHEN SCALING UP “TEST AND TREAT” STRATEGIES

IN LOS ANGELES COUNTY, WHERE THE NUMBER OF PEOPLE DIAGNOSED WITH HIV/AIDS CONTINUES TO GROW, FINDING WAYS TO STOP THE SPREAD OF THE INFECTION IS A PUBLIC HEALTH PRIORITY. SCHAEFFER CENTER SCHOLARS COLLABORATED WITH THE RAND CORPORATION TO FAST FORWARD 10 YEARS TO PREDICT THE EFFECTIVENESS OF A CURRENT TREATMENT STRATEGY.

“TEST AND TREAT” IS A NEW STRATEGY THAT STARTS ANTIRETROVIRAL THERAPY EARLY, EVEN IF HIV-POSITIVE INDIVIDUALS HAVE NO SYMPTOMS. RESEARCH HAS SHOWN THAT EARLY THERAPY BOOSTS CELLS COUNTS AND CAN HELP PREVENT THE SPREAD OF THE VIRUS TO UNINFECTED PARTNERS. HOWEVER, NEERAJ SOOD AND ZACHARY WAGNER FOUND THAT WHILE “TEST AND TREAT” REDUCED THE RATE OF NEW INFECTIONS AND THE NUMBER OF DEATHS, IT HAD A DOWNSIDE. IT ALSO NEARLY DOUBLED THE RATE OF DRUG RESISTANCE.

“WE’RE NOT SAYING THAT TESTING EVERYBODY AND TREATING EVERYBODY IS BAD,” SOOD SAID. “WE’RE SAYING THAT WE SHOULD PROCEED WITH CAUTION AND CLOSELY MONITOR THE PREVALENCE OF MULTI-DRUG-RESISTANT HIV AS WE SCALE UP THE TEST AND TREAT MODEL.”

CHALLENGING THE STATUS QUO ON HIV/AIDS TREATMENT

Preventing drug resistance and improving health outcomes

John Romley

Can Cell Phones Improve Health Outcomes?

TEXTING DIABETES PATIENTS WITH MESSAGES RELATED TO DISEASE CARE MAY HELP THEM CONTROL THEIR DISEASE

APPROXIMATELY ONE IN TEN ADULTS IN THE UNITED STATES HAS TYPE 2 DIABETES. MANY LIVE IN UNSERVED COMMUNITIES WITH FEW OUTPATIENT FACILITIES WHERE THEY COULD RECEIVE EDUCATION AND SUPPORT FOR MANAGING THE DISEASE.

DRA. SANJAY ARORA AND MICHAEL MENCHINE, ASSOCIATE PROFESSORS OF EMERGENCY MEDICINE AT THE KECK SCHOOL OF MEDICINE, KNOW THE IMPORTANCE OF ADHERING TO MEDICATIONS AND CONTROLLING DIET AS A WAY TO MANAGE THE DISEASE. THEY ALSO KNOW THAT THE MOST VULNERABLE PATIENTS WERE OFTEN DOING NEITHER. WHAT WAS NEEDED WAS A LOW-COST SHORT TEXT MESSAGE.

THEIR SOLUTION WAS TO TEXT PATIENTS TWICE DAILY WITH MESSAGES ENCOURAGING THEM TO EAT MORE FRUITS AND VEGETABLES, DO MINDFULNESS EXERCISES, AND STAY AWAY FROM SUGAR. PATIENTS WERE TAPPED INTO THE UBICITY OF CELL PHONES AND DESIGNED A PROGRAM TO TEXT PATIENTS TWICE DAILY WITH MESSAGES TO HELP THEM ADHERE TO MEDICATIONS AND IMPROVE THEIR QUALITY OF LIFE.

“Just putting a dollar sign up doesn’t tell you much. Moving forward, it’s really important for us to examine and understand what’s going on under the hood.”

John Romley

“We should proceed with caution... as we scale up the test and treat model.”

Neeraj Sood
When PBS NewsHour needed an expert to explain the phenomenon of people working decades past traditional retirement age, they turned to Julie Zissimopoulos. With a special interest in the economics of aging, her insight proved to be a valuable contribution to several reports.

Many older workers contribute to the economy by starting their own businesses. Zissimopoulos said they bring a lot to these ventures. “They’re more educated. They have higher income and wealth. They are more willing to take on risks. They have had lots of on-the-job training, lots of work force experience,” she said.

But, if older workers want a more traditional job, it may be harder for them to get hired. “About half of unemployed, middle-aged and older workers are still unemployed two years after losing their job. If you are near retirement and an employer wants to hire you, there’s fixed costs involved. They have to invest in you, and their investment is only going to be spread over a few years compared to a younger worker where that investment might be spread over many more years,” she said.

Many older workers contribute to the economy by starting their own businesses. Zissimopoulos said they bring a lot to these ventures. “They’re more educated. They have higher income and wealth. They are more willing to take on risks. They have had lots of on-the-job training, lots of work force experience,” she said.

But, if older workers want a more traditional job, it may be harder for them to get hired. “About half of unemployed, middle-aged and older workers are still unemployed two years after losing their job. If you are near retirement and an employer wants to hire you, there’s fixed costs involved. They have to invest in you, and their investment is only going to be spread over a few years compared to a younger worker where that investment might be spread over many more years,” she said.

Many older workers contribute to the economy by starting their own businesses. Zissimopoulos said they bring a lot to these ventures. “They’re more educated. They have higher income and wealth. They are more willing to take on risks. They have had lots of on-the-job training, lots of work force experience,” she said.

But, if older workers want a more traditional job, it may be harder for them to get hired. “About half of unemployed, middle-aged and older workers are still unemployed two years after losing their job. If you are near retirement and an employer wants to hire you, there’s fixed costs involved. They have to invest in you, and their investment is only going to be spread over a few years compared to a younger worker where that investment might be spread over many more years,” she said.
Ph.D. in Health Economics

USC’s Ph.D. program in Health Economics is housed at the Schaeffer Center for Health Policy and Economics, one of the leading health policy centers in the nation. The program integrates the curricula from the Departments of Economics, Preventive Medicine, and Pharmaceutical Economics and Policy. Students receive training in microeconomics, econometrics, cost-effectiveness analysis, health economics, public finance, epidemiology, and health status measurement.

Graduates of this program are highly sought for their interdisciplinary background in theoretical and empirical research, and often assume teaching and research positions at universities, in industry, and elsewhere. Competitive fellowships, teaching, and research assistantships are available to students. This program offers two distinct Ph.D. tracks:

(i) Microeconomics: Students in Microeconomics complete the Microeconomic Theory and Economic Sequence and take two advanced courses in Health Economics. They receive focused training and mentoring in health economics through collaboration on research projects led by distinguished health economists at the Schaeffer Center. Upon completion of the Ph.D., students will be well prepared for a research career in academia, think tanks, and other research organizations.

(ii) Pharmaceutical Economics and Policy:

Students in Pharmaceutical Economics and Policy specialize in areas such as cost-effectiveness, comparative effectiveness, and health outcomes research. They collaborate on projects with notable faculty with expertise in Pharmaceutical Economics and Policy. The Schaeffer Center provides support to students who are in Master’s programs through the USC Sol Price School of Policy and the USC School of Pharmacy.

Master of Science in Pharmaceutical Economics and Policy

The USC Pharmaceutical Economics and Policy Master’s program is conducted collaboratively with the Department of Economics, the Department of Preventive Medicine, and the Public Policy program of the USC Price School of Policy. Master’s students are trained to use pharmacoeconomics and assessment techniques in practical decision-making environments such as hospital pharmacies, managed-care pharmacies, third-party payers, and government agencies.

A distinguishing characteristic of the USC Pharmaceutical Economics and Policy Master’s program is the degree to which students are actively engaged in publishable research, either as the lead author or as a secondary author in collaboration with a faculty member.

Master of Health Administration Program

The USC Master of Health Administration (MHA) program has been training leaders in health management and policy for more than 35 years. The MHA is a focused health management and policy degree that offers students breadth and depth in areas of specialization. By enrolling for this degree, students gain access to MHA faculty who are renowned experts in their field, develop strong ties to the healthcare community and gain access to numerous employment opportunities. The program includes a 1,000-hour administrative residency and is accredited by the Commission on Accreditation of Healthcare Management Education (CAHME).
What’s New in Schaeffer Education?

Merkin Brain and Health Policy Fellowship
In 2012, Richard Merkin, Founder, President, and CEO of the Heritage Provider Network, initiated a new fellowship in collaboration with the Keck School of Medicine and the Schaeffer Center. Dr. Merkin, has more than 30 years of experience in health care with specific expertise in the development and administration of integrated delivery systems. His leadership has inspired the formation of more than 200 group model and IPA structures in California, New York, and Arizona.

The program is the response to the need for greater synergy between advances in neuroscience and the devising of policies that improve life outcomes for children, adolescents, and adults experiencing significant risk or adversity due to brain diseases. Housed at the Leonard D. Schaeffer Center for Health Policy and Economics, Director Dana Goldman and Senior Fellow Pat Levitt direct the program. Levitt a Provost Professor of Neuroscience, Pharmacy, Psychiatry, Pediatrics, and Psychology at the Keck School of Medicine of USC.

Healthcare Decision Analysis Master’s Program
The Master’s Program in Healthcare Decision Analysis (HCDMA) is an intensive, interdisciplinary program designed to attract and train graduates from across the globe seeking to improve their technical skills and analytical abilities related to product value, access, and reimbursement. Healthcare Decision Analysis is a newly emerging branch of applied healthcare research that focuses on the intersection of health economics, applied international health policy and insurance design, and competitive business intelligence and pricing. The program provides an opportunity for mid-career working professionals, and new graduates to enter a field in which current managed markets payers, the pharmaceutical and devices industry, healthcare systems and government cannot find sufficient qualified individuals and technically skilled leaders to meet demand. Grant D. Lawless directs this program, which is housed at the Leonard D. Schaeffer Center for Health Policy and Economics.

Post-doctoral Fellow Highlights
Maria Jose Prados is a post-doctoral research scholar at the Schaeffer Center for Health Policy and Economics at the University of Southern California. She finished her Ph.D. in Economics at Columbia University in 2013. Before coming to the US, she studied Economics at the University of California Los Angeles. She graduated from the Johns Hopkins Bloomberg School of Public Health in 2013 with a doctorate in Health Policy and Economics. She also holds a B.S. in Biomedical Engineering from Johns Hopkins University and worked as a research assistant in a stem cell research lab at Harvard University prior to starting graduate school.

Her research focuses on private health insurance markets in the US, including how the Patient Protection and Affordable Care Act (ACA) may affect how these markets function. Her dissertation work focused on the offsetting effects of the level of competition among insurers on health insurance premiums and on how insurance market regulations affect employers’ decisions about the health benefits they offer. Additionally, she has worked on several other research projects related to the ACA including simulations of the population expected to obtain coverage through the exchanges as well as the risk adjustment programs included in the law.

New with RCMAR
Along with Ricardo Basurta-Davila (see page 21), two new scholars have joined the USC-RCMAR, Minority Aging Health Economics Research Center: Leonadro Carvalho and Juan Saavedra, research scientists at the USC Dornsife College of Letters, Arts, and Sciences. Carvalho’s project is to investigate the question: does financial stress affect the minority population’s decision-making? Saavedra’s project is on limited English proficiency and fettered financial capabilities among immigrants. Now finishing the second year of the NIH-funded center the Minority Aging Health Economics Research Center, will host the 2014 Annual Investigators Meeting in Los Angeles. In attendance will be six RCMAR centers and their scholars and faculty.

I chose to work at the Schaeffer Center because I felt that it was an excellent opportunity to further develop my research agenda in an environment surrounded by great collaborators and mentors. I am particularly excited about the chance to work on timely projects related to critical components of health reform and to learn from experts spanning the fields of health policy and economics. I believe that this experience will enable me to continue to develop my research skills and help me be successful in achieving my future research and career goals.”

Erin Trish
“The question with the ACA is: Are the benefits too generous?”

Sacramento Policy Luncheon
February 6, 2013
USC’s Sol Price School of Public Policy and the Leonard D. Schaeffer Center on Health Policy and Economics sponsored a panel which included Peter Lee, Executive Director of Covered California; Dana Goldman, Director of the Schaeffer Center; Bob Kocher, former Special Assistant to President Obama on Healthcare Policy and Economics; and moderated by Jay Hansen, California Medical Association.

According to Lee, 2.6 million Californians will qualify for subsidies on the exchange. About 2.7 million Californians won’t qualify, but will be able to buy unsubsidized insurance on the exchange or outside of it. All of them, he said, will benefit from monumental changes to the insurance market that are part of Obamacare.

“But for this market to work, consumers must make good choices”, said Dana Goldman.

Goldman has studied decision-making among Medicare users purchasing prescription drug coverage, also known as Medicare Part D. He found that many consumers don’t understand basic differences between the available plans and costs. And over time, the number of plans and their benefits have decreased, he said.

To read more, see page 11.

Quintiles Seminar Series
January-December, 2013
The Quintiles Seminar Series is a biweekly series that features prominent academics, researchers, policy makers, and industry leaders to discuss prevalent and current themes in health, policy, and economics. The seminars are topical, relevant presentations of the speakers’ choosing that lead to intimate discussions with the audience.

This past year’s speakers have included academics such as Dr. Ashish Jha, Professor at the Harvard School of Public Health; regulators such as Sir Ian Kennedy, Chair of the Independent Parliamentary Standards Authority in the UK; and former administration officials such as Dr. Bob Kocher, former Special Assistant to the President for Healthcare and Economics Policy.

Affordable Care Act: What Does it Mean for Young People?
October 22, 2013
The Schaeffer Center, in conjunction with the Unruh Institute and the Schwarzenegger Institute, participated in a panel that discussed the impact of the Patient Protection and Affordable Care Act (ACA). The panel, part of a lecture series titled Students Talk Back, consisted of Dana Goldman and Schaeffer Center Pre-Doctoral Fellow Sarah Axon.

The USC Dornsife College of Letters, Arts and Sciences’ Jesse M. Unruh Institute of Politics in conjunction with the Schwarzenegger Institute hosts this weekly discussion of political events that allows the audience to gain valuable insight into each topic.

“T he question is: Are the benefits too generous? Will they grow over time?” Goldman asked the audience. “I don’t think we have to modify the act. If everyone said, ‘Can we make this law work?’ the answer is that actually yes, we just need to figure out maybe we should be less generous and have more penalties.”

2014 Events
Optimizing Medication Safety and Healthcare Quality
February 20-21, 2014
This conference, co-hosted by the USC School of Pharmacy and the Schaeffer Center, in collaboration with the U.S. Department of Health Human Services’ Center for Medicaid and Medicare Innovation. It will bring together a broad cross-section of national healthcare experts and stakeholders for a robust discussion on healthcare quality improvements; Healthcare providers, industry leaders, and government officials are all encouraged to attend.

Topics to be discussed include: Understanding Value-Based Payment Models; Addressing High-Cost, High-Risk Populations; Reaching Patients Where They Live; and Examining Different Perspectives. The purpose of the conference is to help attendees identify quality and safety gaps in the U.S. healthcare system; compare methods of measuring healthcare value; list core components of a highly reliable medication use system; describe proven solutions for achieving the Triple Aim of healthcare reform; explain the alignment between Accountable Care Organizations, commercial health plans to achieve comprehensive medication management programs; and describe proven strategies for reducing readmissions through medication-focused services.

American Society for Health Economics (ASHEcon)
June 22-25, 2014
The Schaeffer Center was selected to host the 2014 American Society for Health Economists (ASHEcon), the premiere conference in health economics. ASHEcon aims to advance health economics research in the United States, to achieve widespread recognition for the field of health economics, and to enhance individual and societal health by providing evidence and expertise for the development of private and public policies.

This four-day event will include plenary events, including Nobel Laureates Daniel McFadden. There will be sixteen concurrent sessions over the course of the conference, with session themes ranging in topic from Healthcare to Cost Effectiveness to Medicare Part D.

American
Society
for
Health
Economics
(ASHEcon)

Sarah Axon (far left) and Dana Goldman (second from left) on a panel discussing the Affordable Care Act.

“Are the benefits too generous?”

Events
Increasing value in health care markets and delivery
Affordable Care Act
Global health
Hospital value
Aer, Jia Jie, and Mike Nichil. “Multiple Medication Adherence and its Effect on Clinical Outcomes Among Patients with Type 2 Diabetes and Comorbid Hypertension.” Medical Care. (2013).
Primary care
Goldman, Dana, John Pasternak, Reid Ryan, and Jeffrey Hoyt. (2013).
Goldman, Dana, John Pasternak, Reid Ryan, and Jeffrey Hoyt. (2013).
Publications


Improving health outcomes for an aging society

Economics of aging / Retirement economics


Disability


Disease-specific projections


Fiscal and macroeconomic consequence


Comparative effectiveness


Fostering better pharmaceutical policy and advertising


Cost-effectiveness


Innovation


Provider behavior


Pharmaceutical markets


Goldman, Dana, Adam Levine, Darius N. Lakdawalla. “What More Value from Prescription Drugs? We Need to let Prices Rise and Fall.” The Economists’ voice. (2013).


Leonard D. Schaeffer, founding Chairman and CEO of WellPoint, current senior adviser to TPG Capital, a private equity firm, and a prominent policy expert in health care financing and delivery whose career spans both the public and private sectors, was elected to the USC Board of Trustees on April 7.

Recognizing the need to bridge the gap between the academic and policymaking communities in order to effectively shape health care reform, Schaeffer and his wife, Pamela, made a gift to establish the USC Leonard D. Schaeffer Center for Health Policy and Economics in 2009. Housed jointly at the USC Sol Price School of Public Policy and the USC School of Pharmacy, the center conducts rigorous interdisciplinary research that is necessary to develop and evaluate solutions for controlling health care costs and improving patient outcomes in the United States and worldwide.

In 2012, Schaeffer made an additional gift of $25 million to endow and support the Center, which is recognized as one of the country’s premier policy institutions. With more than $52 million in external grant funding, the USC Schaeffer Center has responded to the demand for independent information and analysis in many significant policy areas, including aging and Medicare, medical innovation, insurance and pharmaceutical markets, and prevention and value promotion in health care delivery. The Center’s research results and conclusions are routinely communicated in peer-reviewed journals, leading media outlets and directly to policymakers through congressional and legislative testimony and private meetings.

“Leonard Schaeffer has been a driving force in USC’s emergence as a global leader in generating relevant, uniquely interdisciplinary research to inform and influence the health policy debate,” said USC President C. L. Max Nikias. “His leadership and expertise will be invaluable to our Board of Trustees as USC's medical enterprise—encompassing its schools of medicine, policy and pharmacy—assumes an increasingly central role in addressing the health care challenges facing the university, the United States, and the world.”

At USC, Schaeffer holds the Judge Robert Maclay Widney Chair, a select executive-in-residence appointment accorded by the university president and named for one of USC’s founders. In that capacity, Schaeffer teaches a graduate seminar in health care leadership and management, and he lectures in undergraduate courses. He also chairs the advisory board for the USC Schaeffer Center and is a longtime member of the Board of Councilors for the USC Price School.

Excerpted from an article originally written by Annette Moore on news.usc.edu.

“Leonard Schaeffer has been a driving force in USC's emergence as a global leader in generating relevant, uniquely interdisciplinary research to inform and influence the health policy debate.”

USC President C. L. Max Nikias

About the USC Sol Price School of Public Policy
Now in its 85th year, the USC Sol Price School of Public Policy defines excellence and innovation in public affairs education. Ranked 6th nationwide among 266 schools of public affairs, the Price School is dedicated to teaching and research that advances society through better democratic governance, more effective social policy, and sustainable urban development. Price faculty tackle critical societal issues involving health policy, collaborative governance, the environment and sustainability, housing policy, nonprofits and philanthropy, mass emergencies and terrorism, economic development, inequality and equity, transportation, immigration, and globalization, among others. Price graduates shape the world as leaders in government, nonprofit agencies, and the private sector. Through a time-honored commitment to public service, a legacy of strong connections to professional leaders, and a dozen world-renowned research centers the Price School’s mission is to improve the quality of life for people and their communities, here and abroad.

About the School of Pharmacy
Ranked by US News and World Report as a top ten pharmacy school nationwide and first among private schools, the USC School of Pharmacy is recognized for its century-old reputation for innovation in pharmaceutical education. The School uniquely spans the entire spectrum of pharmaceutical development and clinical care—from drug discovery and regulatory approaches that promote safety and innovation, to delivery of patient care services and evaluating the impact of care on patient outcomes and costs. With a history of “firsts” that include the nation’s first PharmD program (1909), first clinical clerkship program (1968), first PhD in pharmaceutical economics (1990), and first professional doctorate in regulatory science (2008), the School is a leader in shaping the pharmaceutical profession to meet the needs of a changing world. In 2013, Dean R. Pete Vanderveen was named Dean of the Year by the American Pharmacists Association. It is also the only school of pharmacy in the nation to have won three Pinnacle Awards, one of pharmacy’s highest honors. Also, Associate Professor Steven Chen was recognized with an American Pharmacists Association Foundation Pinnacle Award, making USC the only school in the nation to have won three Pinnacle Awards, one of pharmacy’s highest honors.

Contributing Writers:
Kathleen Costanza
Stephanie Hecht
Jeremy Loudenback
Robert Muschl
Kerry O’Rourke
Barbara Ray
Dovin Stambler
Sadena Thevarajah
Brisna White